Respiri has signed a two-year definitive service agreement with the Pharmacy Guild of Australia to develop an online training course on optimising asthma patient management, in particular children, including the role of devices that detect wheeze.
The agreement is with the Pharmacy Guild of Australia’s Guild Learning and Development (GuildEd) division.
In terms of the agreement, Respiri and the GuildEd will develop an accredited Continuing Professional Development online training course for pharmacists on optimising asthma patient management focusing on children.
The course will also cover the role of devices in detecting wheeze. This will include Respiri’s wheezo eHealth software as a service device and app, which effectively monitors asthma wheeze.
“With over 65,000 pharmacists practicing in Australia, Respiri understands their importance in helping patients with asthma better-manage their condition – ensuring a better health outcome and quality of life and the critical need for Respiri to build relationships with these key healthcare professionals to help them better understand how wheezo will help drive these patient outcomes,” says Respiri Chief Executive Officer Marjan Mikel.
“By educating pharmacists, who are an important intermediary between an asthmatic patient and their doctor who already sell a range of asthmatic devices within the pharmacy setting, we see them as a critical determinant in building sales momentum and significant growth within this important channel.”
Respiri claims its pioneering technology detects wheeze, which is a typical asthma symptom, and provides an objective measure of airway limitation.
